Adipotide: what the human research actually shows
Adipotide is the peptide that gets pitched on the back of a single monkey fat-loss headline from 2011 and almost never gets pitched with the sentence that comes next: the same primate study and the follow-on human Phase 1 both flagged kidney toxicity. This is the clearest safety case on the site.
Why I looked into this
Adipotide keeps resurfacing on fat-loss forums with a single talking point attached: 11 percent body weight reduction in obese rhesus monkeys over four weeks. That headline is accurate. It is also incomplete in a way that matters a lot if a human reader is deciding whether to acquire a research-use-only compound.
I wanted to see what the full primate paper actually reported, what happened when the compound moved into its one human trial, and why a program that produced that kind of animal headline quietly stopped. The answer is in the literature. It just does not get quoted alongside the monkey number.
What Adipotide actually is
Adipotide, also written as Prohibitin-TP01, is a chimeric peptide. One end (CKGGRAKDC) is a homing motif that binds prohibitin on the endothelial cells lining the blood vessels that feed white adipose tissue. The other end, D(KLAKLAK)2, is a pro-apoptotic membrane-disrupting sequence that only becomes active once it is inside a cell. The design logic is that the homing end docks selectively at fat-vasculature endothelium, the peptide gets internalized, and the KLAKLAK domain triggers programmed cell death in those specific vessels. Starve the fat depot, shrink the fat depot.
The compound was developed by Wadih Arap and Renata Pasqualini and colleagues at MD Anderson Cancer Center. It is fundamentally a cancer-targeting design philosophy retargeted at fat vasculature. That framing matters, because what the design does if it goes wrong is what cancer drugs do when they go wrong.
What the human research shows
Do published human trials exist?
There is no completed efficacy trial of Adipotide as a weight-loss intervention in humans. Zero Phase 2 weight-loss trials, zero Phase 3 trials, no FDA pathway for obesity.
The one human exposure in the published record is NCT01149434, a Phase 1 dose-escalation study in men with metastatic castration-resistant prostate cancer. That trial was not a weight-loss study. It was a cancer safety and pharmacokinetics study that used Adipotide because losing adipose tissue was a secondary consideration and prohibitin expression was of interest in prostate tumor vasculature. The trial recorded adverse events that ended further development.
What evidence actually exists?
The primary published evidence is:
- Barnhart KF, Christianson DR, Hanley PW, et al. Science Translational Medicine, 2011. A 28-day study in obese rhesus monkeys reported roughly 11 percent body weight reduction, selective loss of white adipose tissue, and improved insulin sensitivity. The same paper reported dose-dependent renal proximal tubule injury in the treated animals, with tubular changes described as reversible in the study window but clearly present.
- NCT01149434: Phase 1 dose-escalation of Adipotide (as Prohibitin-TP01) in men with metastatic castration-resistant prostate cancer, sponsored in collaboration with MD Anderson. Published and disclosed adverse events included renal toxicity and hepatic signal. The program did not advance to Phase 2.
- Subsequent literature reviews (2012 onward) consistently frame Adipotide as a proof-of-concept compound whose clinical translation was limited by the renal safety signal observed in both the primate work and the human Phase 1.
What the research does not show
The research does NOT show:
- Safe and sustained fat loss in healthy human adults. The only human exposure is in advanced prostate cancer patients, a population already tolerating a very different risk-benefit calculation.
- That the kidney signal was confined to the monkey work. The human Phase 1 surfaced renal adverse events as well.
- That Adipotide is a validated obesity drug, or ever was close to one. The program was abandoned at the Phase 1 stage.
- That the primate result scales. The 11 percent number is from a narrow-duration, high-dose, heavily monitored primate study with visible kidney findings in the same paper.
- That current research-use-only material is even reliably the same molecule. There is no approved reference product to match a sample against.
The online pitch is a one-sentence extraction from the primate abstract. The honest reading of the full paper, plus the human Phase 1, plus the subsequent silence from the program, is the reason this compound is not on a shelf.
Known safety signals in humans
The Adipotide safety signal in humans is specific and serious. The published Phase 1 in prostate cancer patients recorded renal adverse events, including laboratory findings consistent with tubular injury, and hepatic laboratory signal. These were not minor laboratory drifts in an asymptomatic cohort; they were part of the safety record that ended further clinical development.
The preclinical primate work foreshadowed this. Barnhart 2011 explicitly described dose-dependent proximal tubule changes in rhesus monkeys at the same exposures that produced the fat-loss headline. The design of the molecule, a pro-apoptotic warhead paired with a vascular homing motif, creates a plausible mechanism for off-target endothelial and renal toxicity. The observed signal aligned with that mechanism.
FDA and legal status in the US
There is no active FDA pathway for Adipotide in the United States. It is not approved, it is not in the 503A compounding framework, and it has never been on a PCAC agenda. The one IND-covered human exposure was an oncology Phase 1 that did not advance. No obesity program was ever filed.
The reason matters. FDA-approved obesity drugs in 2026 have multi-thousand-patient outcome trials, structured pharmacovigilance, and defined reference products. Adipotide has none of those. What is sold as Adipotide on the research-use-only market is a compound whose own clinical record is a safety abandonment, not a paused program waiting for better funding.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for Adipotide specifically
The specific source-safety problem with Adipotide is that the compound has no approved reference product, no USP monograph, no enforced identity standard, and a published history of off-target renal injury at in-range primate exposures. A buyer on the research-use-only market has no way to confirm that a given vial contains the intended chimeric peptide, let alone at the stated purity.
The usual peptide identity failures (mis-synthesis, truncation, substitution with cheaper related fragments) are a cosmetic-level concern for some compounds. For Adipotide, where the intended molecule itself produced renal toxicity in its only human trial, identity and purity uncertainty stacked on top of that baseline hazard is a different order of problem.
Cost reality
Expect a wide range of pricing for material labeled as Adipotide on the research-use-only market. A licensed 503A compounding pharmacy is unlikely to compound it under any protocol, given the abandoned clinical program and documented renal signal. Most legitimate clinical infrastructure will not touch this molecule.
Cost is not a quality signal here. The more relevant signal is the near-total absence of Adipotide from any clinician-supervised framework. That absence exists for a reason, and the reason is in the published record.
Questions worth asking any source
- Are you a licensed 503A compounding pharmacy with a verifiable US state license willing to compound this specific molecule?
- Do you provide a certificate of analysis from an independent third-party lab, with mass spectrometry confirming the exact chimeric peptide sequence?
- Do you require a valid prescription from a licensed clinician who has reviewed the Barnhart 2011 renal findings and the NCT01149434 adverse event profile?
- Do you have a physical US address and a phone number I can verify by calling?
- Can you explain, in writing, why you are willing to supply a compound whose sponsor discontinued development for renal toxicity?
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used Adipotide. I would not use Adipotide. If one compound on this site crosses from “the evidence is thin, so be careful” into “the evidence is actively negative,” it is this one. The Barnhart 2011 primate paper and the NCT01149434 Phase 1 are both in the public record, and they both describe renal adverse events at exposures that were also producing the fat-loss headline the internet still quotes.
What bothers me about the Adipotide discourse is the pattern: a single positive animal number lifted out of a paper whose full text is a mixed-signal safety story, then repeated forward until the safety half disappears. I have seen that pattern on multiple peptides on this site. Adipotide is the clearest example, because the safety signal is the reason the sponsor walked away.
The mechanistic design is genuinely interesting. A homing peptide that docks on a specific endothelial target and delivers a pro-apoptotic warhead is a real idea with real clinical applications in oncology. That does not make it a fat-loss product. The margin of error for off-target endothelial apoptosis in a non-life-threatening indication is different from the margin of error in metastatic cancer, and that is the exact distinction the clinical record drew.
For someone who is curious, read the Barnhart 2011 paper in full, not just the abstract, and read the NCT01149434 record. For someone considering use, the honest comparator is not a better fat-loss peptide; it is the FDA-approved GLP-1 and dual-agonist drugs with multi-thousand-patient outcome data. For someone who has already decided to try it: please do not. If any monograph on this site is worth stopping on, it is this one.
Questions to ask your doctor
If you are considering Adipotide, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- I have been reading about Adipotide, including the Barnhart 2011 primate paper and the NCT01149434 Phase 1 in prostate cancer. Given the renal adverse events in both, is there any clinical reason a compound like this would be worth discussing in my situation?
- If someone in my situation were considering a compound with a documented renal toxicity signal, what baseline kidney and liver labs would you want to see, and what would you want to re-check?
- How would you weigh the fact that the sponsor discontinued development after Phase 1, rather than pausing to redesign, compared to what is currently being said about this compound online?
- If fat loss is the actual goal, how would you compare the evidence and risk profile for Adipotide to the FDA-approved GLP-1 and dual-agonist options?
- If I already used this compound and now I am noticing changes in urination, edema, fatigue, or lab values, what should I do and who should I contact first?
- Is there a conventional or FDA-approved option that addresses the outcome I am hoping Adipotide would produce, that we should try or rule out first?
What to do next
Read the full primate paper
Go read Barnhart 2011 in Science Translational Medicine in full, not just the abstract, and the NCT01149434 record on ClinicalTrials.gov. The safety section is the part the forums skip.
Open the primer →Do not skip this conversation
The FDA-approved GLP-1 and dual-agonist drugs have human outcome data at a scale Adipotide will never have. Bring the visit-prep packet to your clinician.
Get the packet →Reconsider
Of every peptide on this site, this is the one where I would ask you to revisit the decision. The renal signal is in the sponsor’s own record.
Open the checklist →Sources
- Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R. “A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.” Science Translational Medicine. 2011 Nov 9;3(108):108ra112. PMID 22072636.
- NCT01149434. “Phase 1 Dose Escalation Study of Prohibitin-TP01 (Adipotide) in Patients with Metastatic Castration Resistant Prostate Cancer.” ClinicalTrials.gov. Registry record.
- Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. “Reversal of obesity by targeted ablation of adipose tissue.” Nature Medicine. 2004;10(6):625-632. The foundational homing-peptide paper that led to the Adipotide program. PMID 15133506.
- Staquicini FI, Cardo-Vila M, Kolonin MG, et al. “Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients.” Proceedings of the National Academy of Sciences. 2011. Background on the prohibitin-targeted vascular homing platform. PMID 22011578.
- Daquinag AC, Zhang Y, Kolonin MG. “Vascular targeting of adipose tissue as an anti-obesity approach.” Trends in Pharmacological Sciences. 2011;32(5):300-307. Independent review of the approach and its translational limitations. PMID 21414673.
The citation floor here is the published record plus the ClinicalTrials.gov registry entry. Every safety claim in this monograph is tied to those primary sources, not to secondary summaries.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
AOD-9604
The other fat-loss peptide whose human data is the unflattering part. A proper Phase 2b was run and did not meet its primary endpoint. Different failure mode, same lesson.
Melanotan-II
The other case on this site where the safety case against the compound is documented in the published literature. Not a fat-loss comparator, a safety-pattern comparator.
Semaglutide
The honest comparator for anyone actually trying to lose weight. FDA approved, Phase 3 outcome data at scale, and a safety record that has been stress-tested in millions of real patients.